Biomarin Pharmaceutical Inc BMRN Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Aug 16, 2023 (filed on Aug 17, 2023)

Insider Name:

Ajer Jeffrey Robert

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-5,000

Price:

$90.00
Aug 10, 2023 (filed on Aug 11, 2023)

Insider Name:

Fuchs Henry J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-12,000

Price:

$90.43
Aug 09, 2023 (filed on Aug 10, 2023)

Insider Name:

Guyer Charles Greg

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-5,360

Price:

$93.30
Aug 08, 2023 (filed on Aug 09, 2023)

Insider Name:

Davis George Eric

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-11,000

Price:

$89.42
Aug 08, 2023 (filed on Aug 09, 2023)

Insider Name:

Bienaime Jean Jacques

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-6,000

Price:

$88.29
Aug 07, 2023 (filed on Aug 09, 2023)

Insider Name:

Bienaime Jean Jacques

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-4,000

Price:

$88.10
Jun 29, 2023 (filed on Jun 30, 2023)

Insider Name:

Mueller Brian

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-576

Price:

$88.93
Jun 29, 2023 (filed on Jun 30, 2023)

Insider Name:

Mueller Brian

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-4,602

Price:

$88.93
Jun 29, 2023 (filed on Jun 30, 2023)

Insider Name:

Mueller Brian

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-4,602

Price:

$88.93
May 23, 2023 (filed on May 24, 2023)

Insider Name:

Slamon Dennis

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

4,190

Price:

--

Filings by filing date

Aug 16, 2023 (filed on Aug 17, 2023)

Insider Name:

Ajer Jeffrey Robert

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-5,000

Price:

$90.00
Apr 28, 2023 (filed on Aug 17, 2023)

Insider Name:

Ajer Jeffrey Robert

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

318

Price:

$66.88
Aug 10, 2023 (filed on Aug 11, 2023)

Insider Name:

Fuchs Henry J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-12,000

Price:

$90.43
Aug 09, 2023 (filed on Aug 10, 2023)

Insider Name:

Guyer Charles Greg

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-5,360

Price:

$93.30
Aug 08, 2023 (filed on Aug 09, 2023)

Insider Name:

Davis George Eric

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-11,000

Price:

$89.42
Aug 08, 2023 (filed on Aug 09, 2023)

Insider Name:

Bienaime Jean Jacques

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-6,000

Price:

$88.29
Aug 07, 2023 (filed on Aug 09, 2023)

Insider Name:

Bienaime Jean Jacques

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-4,000

Price:

$88.10
Jun 29, 2023 (filed on Jun 30, 2023)

Insider Name:

Mueller Brian

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-576

Price:

$88.93
Jun 29, 2023 (filed on Jun 30, 2023)

Insider Name:

Mueller Brian

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-4,602

Price:

$88.93
Jun 29, 2023 (filed on Jun 30, 2023)

Insider Name:

Mueller Brian

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-4,602

Price:

$88.93

News

Biz Brief

Sector: Healthcare	Industry: Pharmaceuticals

See Regulatory Filings on SEC

Company Contact

Address:	105 Digital Dr NOVATO CA 94949-8703
Tel:	N/A
Website:	https://www.biomarin.com
IR:	See website

Key People

Jean-Jacques Bienaime Chairman of the Board, Chief Executive Officer	Brian R. Mueller Chief Financial Officer, Executive Vice President - Finance	Henry J. Fuchs President - Worldwide Research and Development
C. Greg Guyer Executive Vice President - Global Manufacturing and Technical Operations, Chief Technical Officer	G. Eric Davis Executive Vice President, Secretary, Chief Legal Officer	Jeff Robert Ajer Executive Vice President, Chief Commercial Officer
Erin Burkhart Group Vice President, Chief Accounting Officer

Business Overview

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops and commercializes therapies that address the root cause of genetic conditions. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Roctavian (valoctocogene roxaparvovec) and Voxzogo (vosoritide). The Roctavian is an adeno associated virus (AAV5) vector drug development candidate designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. The Company's clinical development programs include BMN 331, an AAV5 mediated gene therapy for people living with Hereditary Angioedema (HAE) and BMN 255 is a small-molecule therapy that is designed to treat hyperoxaluria in chronic liver disease.

Financial Overview

For the six months ended 30 June 2023, Biomarin Pharmaceutical Inc revenues increased 13% to $1.19B. Net income decreased 28% to $106.9M. Revenues reflect Voxzogo segment increase from $54M to $201.2M, Palynziq1 segment increase of 18% to $137.2M, Middle East segment increase of 79% to $117.3M, United States segment increase of 12% to $358.4M. Net income was offset by Gain on sale of nonfinancial assets decrease from $108M (income) to $0K.

Employees:	3,082 as of Dec 31, 2022

Reporting Currency:	U.S. Dollars
Enterprise value:	$16,628M as of Jun 30, 2023
Annual revenue (TTM):	$2,235M as of Jun 30, 2023
EBITDA (TTM):	$192.50M as of Jun 30, 2023
Net annual income (TTM):	$99.99M as of Jun 30, 2023
Free cash flow (TTM):	$40.91M as of Jun 30, 2023
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	188,174,773 as of Jul 28, 2023
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization